{
    "clinical_study": {
        "@rank": "97552", 
        "arm_group": {
            "arm_group_label": "GLA-SE", 
            "arm_group_type": "Experimental", 
            "description": "Glucopyranosyl Lipid A in Stable Emulsion"
        }, 
        "brief_summary": {
            "textblock": "This is a single arm, open-label, single center study evaluating  the safety, feasibility,\n      clinical efficacy and immunogenicity of GLA-SE administration to patients with Merkel cell\n      carcinoma.  Ten patients will be treated.  The goal is for GLA-SE to assist the patient's\n      own immune system in attacking the cancer cells."
        }, 
        "brief_title": "A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Merkel Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Merkel Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single arm, open-label, single center study evaluating  the safety, feasibility,\n      clinical efficacy and immunogenicity of GLA-SE administration to patients with Merkel cell\n      carcinoma.  Ten patients with metastatic or locoregional disease will be treated.  The goal\n      is for GLA-SE to assist the patient's own immune system in attacking the cancer cells."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy-confirmed Merkel cell carcinoma with metastatic or loco-regional disease.\n\n          -  Patients must have at least one injectable lesion, defined as an easily palpable\n             superficial lesion (cutaneous, subcutaneous or lymph nodal metastasis) that can be\n             accurately localized, stabilized by palpation, and is superficial enough to enable IT\n             injection.\n\n          -  ECOG performance status score 0, 1 or 2\n\n          -  \u2265 18 years of age\n\n          -  Life expectancy of \u2265 three months.\n\n          -  Adequate neutrophil and platelet counts\n\n          -  Adequate renal and hepatic function\n\n          -  Willing to undergo pre-treatment lesion biopsy and post-treatment lesion biopsy\n\n          -  Use of effective contraception\n\n          -  Signed informed consent document\n\n          -  Members of all genders, races and ethnic groups are eligible for this trial\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy or a major surgical procedure within 3 weeks, or radiotherapy\n             within 2 weeks prior to first study treatment\n\n          -  No concurrent anti-cancer treatment (including topical agents such as imiquimod) or\n             investigational agents\n\n          -  Active, untreated brain metastases\n\n          -  Pregnant or nursing\n\n          -  Use of any systemic immunosuppressive agents\n\n          -  Immunosuppressed patients\n\n          -  Uncontrolled depression or other major psychiatric disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035657", 
            "org_study_id": "IDC-G100-2013-001"
        }, 
        "intervention": {
            "arm_group_label": "GLA-SE", 
            "description": "Glucopyranosyl Lipid A in Stable Emulsion", 
            "intervention_name": "GLA-SE", 
            "intervention_type": "Biological", 
            "other_name": "Glucopyranosyl Lipid A in Stable Emulsion"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Merkel cell carcinoma", 
            "MCC"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "email": "mgd@uw.edu", 
                "last_name": "Mike Donahue, BS", 
                "phone": "206-288-7058"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "University of Washington Medical Center, Seattle Cancer Care Alliance"
            }, 
            "investigator": {
                "last_name": "Shailender Bhatia, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma", 
        "overall_contact": {
            "email": "frank.hsu@immunedesign.com", 
            "last_name": "Frank Hsu, MD", 
            "phone": "650-887-6703"
        }, 
        "overall_contact_backup": {
            "email": "scott.houston@immunedesign.com", 
            "last_name": "Scott Houston", 
            "phone": "650-887-6703"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of treatment-related adverse events", 
            "measure": "Safety and feasibility", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary objectives are to assess the clinical efficacy of as well as the immunological effects of GLA-SE in patients with MCC", 
                "measure": "Clinical efficacy and Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "description": "Objective tumor response rate, time to progression or relapse, survival, and cellular immune activation", 
                "measure": "Clinical efficacy and Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }
        ], 
        "source": "Immune Design", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immune Design", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}